All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-EGFR chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human EGFR. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFR antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of Melanoma.
CAR Construction : Fig.1 Cell-surface EGFRs were measured by FACS with flow cytometry. The cells were collected for FACS analysis of the distribution of FITC-positive cells. Decreased levels of total and cell-surface EGFR in DiFi5 cells relative to parental DiFi cells. Lu, Y., Li, X., Liang, K., Luwor, R., Siddik, Z. H., Mills, G. B., ... & Fan, Z. (2007). Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer research, 67(17), 8240-8247. |
CAR Construction : Fig.2 Flow cytometric analysis of BaF/3. Data are representative of binding observed in all samples. Perera, R. M., Zoncu, R., Johns, T. G., Pypaert, M., Lee, F. T., Mellman, I., ... & Scott, A. M. (2007). Internalization, intracellular trafficking, biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. Neoplasia, 9(12), 1099-1110. |
CAR Construction : Fig.3 Differential sensitivity of EGFRvIII monoclonal antibodies DH8.3/Ab-18 and 4-5H by FACS analysis. All mAbs recognized EGFRvIII on the cell surface, mAb 528 recognized both wild-type EGFR and EGFRvIII, whereas mAbs 4-5H and DH8.3/Ab-18 recognized EGFRvIII only. Yu, H., Gong, X., Luo, X., Han, W., Hong, G., Singh, B., & Tang, C. K. (2008). Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways. Cancer Biology & Therapy, 7(11), 1818-1828. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-EGFR (MAb528) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-ZP8034). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION